JPMorgan Chase & Co. reissued their overweight rating on shares of Relx (LON:REL) in a report released on Friday morning, Borsen Zeitung reports. The brokerage currently has a GBX 2,000 ($24.61) price objective on the stock.

Several other research firms also recently commented on REL. Liberum Capital reissued a buy rating on shares of Relx in a report on Wednesday, April 8th. UBS Group reissued a neutral rating and set a GBX 1,790 ($22.03) price objective (down previously from GBX 1,790 ($22.03)) on shares of Relx in a report on Thursday, May 28th. Barclays increased their price objective on shares of Relx from GBX 1,860 ($22.89) to GBX 1,910 ($23.50) and gave the company an overweight rating in a report on Thursday, April 9th. Goldman Sachs Group reissued a buy rating and set a GBX 2,189 ($26.94) price objective on shares of Relx in a report on Wednesday, April 8th. Finally, Kepler Capital Markets reaffirmed a neutral rating and issued a GBX 1,915 ($23.57) price target on shares of Relx in a report on Tuesday, May 5th. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Relx presently has an average rating of Buy and an average price target of GBX 1,977.40 ($24.33).

REL opened at GBX 1,903.50 ($23.42) on Friday. The firm has a 50-day simple moving average of GBX 1,873.18 and a two-hundred day simple moving average of GBX 1,866.14. Relx has a 52 week low of GBX 1,382.86 ($17.02) and a 52 week high of GBX 2,109 ($25.95). The company has a market capitalization of $37.07 billion and a PE ratio of 24.62. The company has a quick ratio of 0.33, a current ratio of 0.41 and a debt-to-equity ratio of 293.11.

About Relx

RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.

Read More: What is the Rule of 72?

Analyst Recommendations for Relx (LON:REL)

Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.